Ian Haydock's profile photo

Ian Haydock

Tokyo

Editor-in-Chief, Asia-Pacific at Scrip

Editor-in-Chief, Asia-Pacific at The Pink Sheet

Tokyo-based Editor-in-Chief, Asia-Pacific, for @PharmaScrip @PharmaPinkSheet, @citeline, @NorstellaCo. All views my own, RTs not endorsements.

Featured in: Favicon informa.com (+5) Favicon pharmamedtechbi.com Favicon biospectrumasia.com Favicon pharmaceuticalmanufacturer.media Favicon citeline.com (+1)

Articles

  • Quick Listen: Scrip’s Five Must-Know Things

    1 week ago | insights.citeline.com | Ian Haydock

    Quick Listen: Scrip’s Five Must-Know Things In this week's episode: Trump’s tariff rollercoaster; regulatory, economic uncertainties hang over Q1 earnings; IPOs rise in Q1 but may slow; Chinese deal-making matures; and AstraZeneca talks about Chinese innovation. weekly audio roundup of selected content from Scrip's global team

  • Quick Listen: Scrip’s Five Must-Know Things

    2 weeks ago | insights.citeline.com | Ian Haydock

    Quick Listen: Scrip’s Five Must-Know Things In this week's episode: pharma dodges tariffs for now; Marks’s departure from FDA rattles industry; Phase 2b win for AstraZeneca’s oral PCSK9; Hengrui renews global Phase 3 push; and Novo’s new cardio results for semaglutide. weekly audio roundup of selected content from Scrip's global team

  • Sumitomo Offloads Asia Pharma Ops To Marubeni For $480m

    3 weeks ago | insights.citeline.com | Ian Haydock

    Sumitomo Offloads Asia Pharma Ops To Marubeni For $480m Latest In String Of Restructuring MovesThe latest in a long line of restructuring moves will see Sumitomo Chemical selling its pharma operations in Asia to major Japanese trading house Marubeni. Japanese trading giants agree on Asia pharma deal • Source: Alamy

  • Quick Listen: Scrip’s Five Must-Know Things

    3 weeks ago | insights.citeline.com | Ian Haydock

    Quick Listen: Scrip’s Five Must-Know Things In this week's episode: Merck & Co. licenses Hengrui’s lipid lowerer; Novo gets United’s triple G obesity drug; J&J plans major US manufacturing investments; approval for GSK’s novel antibiotic; and a call for more aggressive Korean M&A activity. weekly audio roundup of selected content from Scrip's global team

  • Quick Listen: Scrip’s Five Must-Know Things

    1 month ago | insights.citeline.com | Ian Haydock

    Quick Listen: Scrip’s Five Must-Know Things In this week's episode: Pfizer tops pharma leaderboard; AstraZeneca buys into in vivo cell therapy; Almirall looks to dominate derma spectrum; Incyte’s HS contender looks approvable; and MSD’s Williams says pharma should shorten tech adoption cycles. weekly audio roundup of selected content from Scrip's global team

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
982
Tweets
9K
DMs Open
No
Ian Haydock
Ian Haydock @ScripIanHaydock
11 Apr 25

Thanks to everyone who attended my session on the @citeline Annual R&D Report at #CPHIJapan yesterday! @norstella (Photo: @scriplisatakagi) https://t.co/AnChHMt8aS

Ian Haydock
Ian Haydock @ScripIanHaydock
11 Apr 25

RT @scriplisatakagi: CPHI Japan 2025 has @ScripIanHaydock presenting global R&D trends from Citeline. Cancer remains at the top focus with…

Ian Haydock
Ian Haydock @ScripIanHaydock
7 Apr 25

RT @PharmaScrip: Quick Listen: Scrip’s Five Must-Know Things https://t.co/q8r59qH2eV #PharmaScrip https://t.co/4LEQO4X6Na